On my (possibly wrong) calculations, we have market cap to trailing twelve month revenue ratio of about 10.5 ???Can anyone else confirm?
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%